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Introduction: Her-2/neu overexpression is linked to poor prognosis and is a signiﬁcant predictor of the
response to trastuzumab (i.e., herceptin) therapy in breast cancer patients. Her-2/neu promotes angio-
genesis with thrombospondin-1 (TSP-1) as a mediator in breast cancer development and progression.
However, the clinical quantitative evaluation of Her-2/neu and speciﬁed localization of TSP-1 are
currently lacking.
Materials and methods: In this study, immunohistochemistry was performed to elucidate the in vivo
relationships between Her-2/neu and TSP-1 expression, angiogenesis, and lymphangiogenesis in breast
cancer. Based on immunohistochemical staining for anti-Her-2/neu and related quantitative scoring of
tumor cells, 28 individuals with high Her-2/Neu expression (i.e., with a score of 2.0) were recruited into
the study group. Another 28 individuals with low Her-2/neu (i.e., with a score of <2.0) were recruited for
comparison. These tumors were further stained immunohistochemically for the estrogen receptor (ER),
the progesterone receptor (PR), Ki-67, TSP-1, CD31 (an vascular endothelial marker), and D2-40 (a
lymphatic endothelial marker).
Results: The individuals with Her-2/neu overexpression had signiﬁcantly lower ER and PR expression and
a higher Ki-67 index, microvessel count, and lymphatic vessel density in comparison to the individuals
with low Her-2/neu expression. High Her-2/neu expression was associated with lower TSP-1 expression
in tumor cells (TSP-1/T) and higher TSP-1 expression in the adjacent stroma (TSP-1/S; 17 of 28 in-
dividuals). By contrast, low Her-2/neu expression was associated with high TSP-1/T expression and low
TSP-1/S (23 of 28 individuals). In one situation, patients with high expression of TSP-1 in tumor cells (a
score of >2.0, with 2.0 as the cut-off value) had a signiﬁcantly lower microvessel density, compared to
individuals with low-TSP-1 expression (p ¼ 0.018). However, the lymphatic vessel density was not
signiﬁcantly different from the TSP-1 levels (p ¼ 0.333).
Conclusion: Our in vivo results showed that Her-2/neu affects the biologicalmanifestations of breast cancer
by increasing angiogenesis (which is TSP-1-related) and lymphangiogenesis, which is TSP-1-unrelated).
Copyright  2013, The Asia-Paciﬁc Association for Gynecologic Endoscopy and Minimally Invasive
Therapy. Published by Elsevier Taiwan LLC. All rights reserved.gy and Pelvic Floor Recon-




Overexpression of the human epidermal growth factor receptor-
2 (Her-2/neu) occurs in 25e30% of breast cancers and is linked to a
more aggressive disease course.1 The Her-2/neu (also referred to as
c-erbB-2) oncogene is a member of the erbB-like oncogene family;
its ampliﬁcation aggravates tumor proliferation, migration,ndoscopyandMinimally InvasiveTherapy.PublishedbyElsevierTaiwanLLC.All rightsreserved.
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detection of Her-2/neu oncogene ampliﬁcation is necessary for
selecting cancer patients for recombinant monoclonal antibody
trastuzumab (i.e., herceptin) therapy against Her-2/neu (Genetech
Inc, South San Francisco, CA, USA), the monoclonal anti-Her-2/neu
antibody, and for providing prognostic information.1 Herceptin
plays a novel role in antiangiogenic therapy in breast cancer by
inducing normalization and regression of the vasculature in an
experimental human breast tumor that overexpresses Her-2/neu in
mice. It works by modulating the effects of different angiogenesis
activators and inhibitors, including the downregulation of angio-
genic inhibitors, [e.g., thrombospondin-1 (TSP-1)] and reducing
angiogenic activators [e.g., vascular endothelial growth factor
(VEGF)].5 The knockdown of Her-2/neu expression by RNA inter-
ference (RNAi) is associated with the upregulation of TSP-1.4
However, the quantitative evaluation and clinical correlation of
Her-2/neu-induced angiogenesis and lymphangiogenesis is lacking.
Among themediators of Her-2/neu, the thrombospondins (TSPs)
are a family of extracellular proteins that participate in cell-to-cell
and cell-to-matrix communication.6 Of the ﬁve family members,
TSP-1 (an endogenous angiogenic inhibitor) plays an important
role in the angiogenic switch in carcinomas of the skin,7 prostate,8
bladder, and cervix.9 It has multiple diverse functions such as a
proinvasive role in in vitro and in vivo models of breast cancer.10,11
However, TSP-1 has been linked with stimulatory12,13 and with
inhibitory14,15 roles in tumor invasion and progression. The over-
expression of TSP-1 is able to block in vivo neovascularization and
decrease malignant tumor growth.14,16 However, TSP-1 promotes
tumor cell adhesion, migration, and invasion.12 Thus, TSP-1 has
controversially been described as having a dual role as a tumor
suppressor and tumor promoter, and a proinvasive and antiangio-
genesis role. The presence of TSP-1 expression in stromal cells (i.e.,
desmoplasia) is correlated with higher microvessel density
(MVD)17; however, there is a lack of speciﬁc localization of TSP-1 in
either tumor or stromal cells in breast cancer.
The aim of this study was to develop a quantitative measure-
ment and to investigate clinical correlations of Her-2/neu and its
mediator TSP-1dwhich acts as an endogenous fence to inhibit
angiogenesis that occurs during early carcinogenesis9 and plays a
potential physiologic gatekeeper role in cancer prevention18din
regulating angiogenesis and lymphangiogenesis in breast cancer. In
addition to angiogenesis, lymphangiogenesis (i.e., the formation of
new lymphatic vessels) has recently drawn considerable attention
and has become a new frontier of tumor metastasis research.19
With the advancement in the development of new antibodies,
lymphatic microvessels can be detected and measured with
appropriate antibodies. A selective monoclonal immunohisto-
chemical marker, D2-40, was used to detect lymphatic invasion in
conventionally processed formalin-ﬁxed and parafﬁn-embeddedTable 1
The clinicopathologic parameters of the high Her-2/neu and low Her-2/neu groups.
Group High Her-2/neu Low Her-2/neu p
2 <2
No. 28 28
Her-2/neu 2.76  0.74 0.89  0.46
Age 52.8  11.7 56.5  13.4 0.266
Grade I 2 16 <0.001
II 8 5
III 18 7
Tumor size T1 20 24 0.329
T2 7 4
T3 1 0
Lymph nodea þ 7 (25.0) 8 (28.6) 0.763
Data are expressed as mean  SD or n (%).
a Fisher’s exact test was used to analyze tumor size.tissue specimens.20 To provide a more objective and sophisticated
method for immunohistochemistry stains, we used the Automated
Cellular Imaging System (ACIS) digital microscope (ChromaVision
Medical Systems, San Juan Capistrano, CA, USA), which combines
automated digital microscopy and computerized image processing;
ACIS is less time consuming and less dependent on the experience
of analysts in characterizing breast cancers, compared to tradi-
tional, manual light microscopy.21 In this study, we used the ACIS to
evaluate Her-2/neu and TSP-1 in a more objective and quantitative
way. We also speciﬁcally localized TSP-1 expression separately in
tumor and stromal cells.
Materials and methods
Specimen samples
From January 2004 to September 2004, specimens of stage I or
stage II invasive ductal or lobular invasive breast cancer were
collected at WCP Pathology Laboratories, Inc. (St. Louis, MO, USA)
by using the standard procedure described later. Her-2/neu protein
expression of each tumor was quantitatively measured by using an
ACIS, and ranged from 0.5 to 3.0. Twenty-eight patients with high
Her-2/neu expression (i.e., a score of 2.0) were recruited into the
study group; another 28 patients with low Her-2/neu expression
(i.e., a score of <2.0) were recruited as the comparison group.
Table 1 provides other clinicopathological features of these 56 pa-
tients (e.g., age, histological grading, tumor size, and lymph node
metastasis) that were obtained through reviewing their medical
records. Representative parafﬁn-embedded tissue blocks from
these patients were selected for additional immunohistochemical
staining, which included staining for TSP-1, CD31, and D2-40. A
detailed description follows.
Immunohistochemical staining
Specimens of invasive ductal or lobular breast carcinoma were
stained immunohistochemically for Her-2/neu protein expression
by using the anti-Her-2/neu antibody CBE-356 (dilution of 1:150;
Novocastra Laboratories, Newcastle upon Tyne, UK) by using the
Bond-max autostainer (Vision Biosystem, Norwell, MA, USA). Other
antibodies and dilution concentrations were as follows: estrogen
receptor (ER, 1:100), progesterone receptor (PR, 1:100), Ki-67
(1:30), p53 (1:400), and TSP-1 (1:150), which were all obtained
from Novocatra Laboratories; CD31 (1:100), obtained from Ventana
Medical System, Inc, (Tucson, AZ, USA); and D2-40 (1:40), obtained
from Signet Laboratories (Dedham, MA, USA). The protocol for Her2
immunohistochemical assays has been described elsewhere.22 In
brief, parafﬁn-embedded tissue blocks were cut to 5-mm sections,
deparafﬁnized, and heat treated for antigen retrieval. The primary
polyclonal anti-Her-2/neu antibody, CBE356, chosen as previously
described, was used at the optimal dilution of 1:150 determined in
our laboratory. Biotinylated secondary antibody with streptavi-
dinbiotin labeling and related reagents were provided in the level 2
USA UltraStreptavidin Multi-Species Detection System (Signet
Laboratories). All immunohistochemical assays were performed on
an automated immunostainer. A positive immunohistochemical
reaction was deﬁned as a dark brown reaction product on the cell
membrane. Positive controls, (e.g., spleen, thymus, placenta) were
used in accordance with the manufacturer’s user manual.
ACIS
Digital microscopy was performed with the ACIS digital mi-
croscope (ChromaVision Medical Systems). The ACIS system con-
sists of an automated robotic bright-ﬁeld microscope module, a
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botic microscope module scanned the immunohistochemically
stained slides, and a computer monitor displayed the digitized
tissue images. The images were captured with an analog camera
and digitizer, transformed into pixels, and then quantiﬁed by hue
(i.e., color), saturation (i.e., color purity), and luminosity (i.e., in-
tensity). The ACIS was implemented for routine operation in the
WCP Laboratories. Membrane staining was not highlighted on the
image; however, the ACIS system was able to distinguish cell
membrane staining from cytoplasmic staining by using color space
transformation (CST) proprietary technology. The ACIS then spe-
ciﬁcally quantitated Her-2/neu protein staining on cell membrane.
In this study, immunohistochemical staining was quantitated
[without knowledge of the manual immunohistochemical or
ﬂuorescence in situ hybridization (FISH) scores] by using the
manufacturer’s preset circular marks to select the areas of invasive
tumor cells. The ACIS recognized 256 levels of immunohisto-
chemical staining intensity and converted these to fractional
scores for the selected individual cells. An average score for all
selected areas also was calculated.
Scoring and quantitation
The manufacturer recommended quantitation of ﬁve areas with
the highest staining intensity. In this study, six areas of invasive
component with highest staining intensity were quantitated to
reduce potential sampling variations. The ACIS measured the
average positive percentage of ER, PR, Ki67, and p53. A positive
result for ER or PR was deﬁned as >5% of the tumor cells staining
positive for ER or PR; for Ki-67, 20% of cells staining positive; and for
p53, 10% of cells staining positive.24,25 The average staining in-
tensity of Her-2/neu was measured by ACIS. Patients with an
average score of 2.0 or higher were considered to have Her-2/neu
protein overexpression and classiﬁed in the high Her-2/neu group.
The patients with an average score <2.0 were classiﬁed in the low
Her-2/neu group. Similar techniques and principles were applied to
determine the TSP-1 level by using the same cut-off score of 2.0.
Patients with an average score of 2.0 were classiﬁed in the high
TSP-1 group, whereas patients with an average score lower than 2.0
were classiﬁed in the low TSP-1 group. The observers (MPW) were
blinded with regard to the staging information and demographic
characteristics of the patients.
Vascular microvessel density and lymphatic vessel density
Vascular microvessel density, although it has some inherent
limitations, is a very commonly used quantitative assessment of
tumor vasculature. The hotspots were measured within isolated
regions of high vessel concentration by using different vascular
endothelial markers.26We used anti-CD31 to stain blood and D2-40
to stain lymphatic vessels. The monoclonal antibody D2-40, which
reacts with the oncofetal membrane antigen M2A, is a new selec-
tive marker for the lymphatic endothelium, and is useful in iden-
tifying the presence of lymphatic invasion in various malignant
neoplasms.27 To identify areas of capillaries, sections were scanned
at low magniﬁcation (10 objective lens). The vessels that were
deﬁned as any positively stained single cell or cluster of cells were
counted for MVD to measure the number of vessels per high-power
microscopic ﬁeld (40 objective lens). The MVD was scored in
three ﬁelds of each lesion by the microvessel counting protocols
and criteria developed by Weidner et al28 with minor modiﬁca-
tions. Microvessels or lymphatic vessels were deﬁned as CD31-
positive, D2-40-positive, or circular structures. Other isolated or
clusters of positive cells were not included. Two investigators
performed simultaneous quantitation by using a multi-headedmicroscope. They had to concur on the areas to be analyzed and
on vessel identiﬁcation numbers and counts.
Statistical analysis
The Chi-square test was used for data analysis, which included
age, histologic grade, lymph node metastasis, ER, PR, and Ki-67
status. The Fisher’s exact test was used for the analysis of tumor
size and p53. All values of Her-2/neu, TSP-1, MVD, and lymphatic
vessel density (LVD) were reported as the mean  the standard
deviation (M  SD). The Student t test was used to analyze Her-2/
neu, TSP-1, MVD, and LVD. A p value < 0.05 was considered sig-
niﬁcant. The Pearson correlation coefﬁcient (r) was used to eval-
uate the correlation of Her-2/neu with MVD and LVD and the
correlation of TSP-1 with MVD and LVD. A p value < 0.05 was
considered statistically signiﬁcant. In this study, a retrospective
power analysis was performed to determine the association of
MVD and LVD with the high and low Her-2/neu groups. In accor-
dance with the observed data, this analysis showed that the study
had approximately 99% power (high Her-2/neu group) and 91%
power (low Her-2/neu group) to detect a signiﬁcant difference
(effect sizes were 5.9 and 1.4, respectively), assuming a signiﬁ-
cance level of a ¼ 0.05.
Results
Clinicopathologic parameters and ER, PR, Ki-67, and p53 status in
the different Her-2/neu groups
By using the ACIS, we evaluated Her-2/neu in a more objective
and quantitativemanner with scores ranging from 0.5 to 3.0 (Fig.1).
Compared to the low Her-2/neu group, the high Her-2/neu group
had a higher histologic grading (p < 0.001), but no signiﬁcant dif-
ference in tumor size (p < 0.329) or lymph node metastasis
(p< 0.763; Table 1). However, the high-Her-2/neu group had less ER
expression, less PR expression, and more Ki-67 expression
(p < 0.001, p < 0.001, p < 0.001, respectively; Table 2). More p53-
positive results (photos not shown) was found in the high Her-2/
neu group, although this was not statistically signiﬁcant (p ¼ 0.051;
Table 2).
Her-2/neu overexpression is associated with high MVD and LVD
We evaluated angiogenesis by the immunohistochemical
staining of CD31 for MVD (Fig. 2A and B) and D2-40 for lym-
phangiogenesis assessment (i.e., LVD; Fig. 2C and D). Angiogenesis
was signiﬁcantly higher in the high Her-2/neu group than in the
low Her-2/neu group (p < 0.001). The speciﬁcity of D2-40 for
lymphatic vessels was demonstrated in which some arterioles with
lumen-like characteristics showed no staining for D2-40. This can
provide further evidence of the speciﬁcity of D2-40 for lymphatic
vessels instead of blood vessels. The lymphangiogenic response
was signiﬁcantly higher in the high Her-2/neu group than in the
low Her-2/neu group (p ¼ 0.002; Table 2).
Her-2/neu overexpression is correlated with low TSP-1 expression in
tumor cells and high TSP-1 expression in the stromal area
The ACIS was used to quantitate and speciﬁcally localize TSP-1
expression in the tumor cells and in the surrounding stromal
cells, respectively. Individual scores and statistical analysis showed
that the high Her-2/neu group had a signiﬁcantly low expression of
TSP-1 in tumor cells (TSP-1/T; p < 0.001) and high expression of
TSP-1 in stromal cells (TSP-1/S; p < 0.001), compared to the low
Her-2/neu group (Table 2). We found two distinct expression
Fig. 1. Representative photographs of immunohistochemical stains for different levels of Her-2/neu expression, ranging from low expression (0.5) to high expression (3.0).
Characteristic scores (i.e., 0.5, 1.0, 1.5, 2.0, 2.5, and 3.0) from the ACIS scoring system are shown. The scale bar represents 2.5 mm.
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that low TSP-1/T was associated with high TSP-1/S (Fig. 3A and B)
and pattern II showed that high TSP-1/T was associated with low
TSP-1/S (Fig. 3C and D). In both patterns, TSP-1/T and TSP-1/S often
manifestly compensated each other. Pattern I manifested more
commonly in the high Her-2/neu group, whereas pattern IITable 2
Comparison of ER, PR, Ki-67, p53, MVD, LVD between the high Her-2/neu and low
Her-2/neu groups.
Cutoff (%) High Her-2/neu Low Her-2/neu p
2 <2
ER 5 9 (32.1) 23 (82.1) <0.001
PR 5 4 (14.3) 16 (57.1) 0.001
Ki-67 20 26 (92.9) 13 (46.4) <0.001
p53 10 7 (25.0) 1 (3.6) 0.051
MVD 13.8  2.4 7.9  3.6 <0.001
LVDa 4.4  1.6 3.0  1.5 0.002
TSP-1/T 1.69  0.62 2.54  0.58 <0.001
TSP-1/S 2.44  0.64 1.51  0.48 <0.001
Data are expressed as mean  standard deviation or n (%).
ER ¼ estrogen receptor; LVD ¼ lymphatic vessel density; MVD ¼ microvessel
density; PR ¼ progesterone receptor; TSP-1 ¼ thrombospondin-1; TSP-1/S ¼ TSP-1
expression in the stroma; TSP-1/T ¼ TSP-1 expression in tumor cells.
a Fisher’s exact test was used for the analysis of tumor p53 status.manifestedmore commonly in the lowHer-2/neu group. In the high
Her-2/neu group, there were 17 patients with pattern I; four pa-
tients with pattern II; and seven patients with concordant
expression (four patients had high TSP-1 expression in the tumor
and stromal cells and three patients had low TPS-1 expression in
both cell types). In the low Her-2/neu group, there were four pa-
tients with pattern I, 23 patients with pattern II, and one patient
with concordant expression (i.e, high TPS-1 expression in both cell
types).TSP-1 expression is correlated with different MVD levels, but not
with LVD
We further compared angiogenesis in the different TSP-1
expression groups. For statistical analysis, the patients with
different TSP-1 scores were categorized into the high TSP-1 group
or low TSP-1 group with a cut-off value of 2.0 by using the same
principles in measuring Her-2/neu with ACIS. The MVD was
signiﬁcantly lower in the high TSP-1/T group (p ¼ 0.018) and
signiﬁcantly higher in the high TSP-1/S group (p ¼ 0.015),
compared to the low TSP-1/T group. The LVD was not signiﬁcantly
different in the TSP-1/T group (p ¼ 0.333) or in the TSP-1/S group
(p ¼ 0.372; Table 3). In summary, the expression of Her-2/neu was
positively correlated with angiogenesis and lymphangiogenesis
Fig. 2. Representative photographs of immunohistochemical stains for two blood vessels (i.e., CD31-stain) and lymphatic vessels (i.e., D2-40 stain). The blood vessels are deﬁned as
a positive CD31-stained tube or circular structure, and viewed through the objective lens of the microscope at (A) 10magniﬁcation and at (B) 40magniﬁcation. Lymphatic vessels
are deﬁned as D2-40-stained tube or circular structures, and are shown at (C) 100 magniﬁcation and at (D) 400 magniﬁcation. Isolated or clusters of positively stained cells are
not included. Some arterioles with characteristic lumen-like structures show no D2-40 staining, which provides evidence of the speciﬁcity of D2-40 for lymphatic vessels, instead of
blood vessels. The scale bar represents 40 mm (A, C), 10 mm (B, D).
M.-C. Hong et al. / Gynecology and Minimally Invasive Therapy 2 (2013) 114e121118(for both, p < 0.001; Fig. 4). The TSP-1/T was negatively correlated
with angiogenesis (p ¼ 0.002), whereas the TSP-1/S was positively
correlated with angiogenesis (p < 0.001). Neither TSP-1/T nor TSP-
1/S was correlated with lymphangiogenesis (p ¼ 0.138 and
p ¼ 0.185, respectively; Fig. 4).Fig. 3. Two TSP-1 expression patterns are demonstrated: pattern 1 is low thrombospondin-1
in the stroma area (TSP-1/S), shown at (A) 100 magniﬁcation and at (B) 400 magniﬁ
magniﬁcation and at (D) 400 magniﬁcation. The scale bar represents 10 mm (A, C) and 2.Discussion
Our study is the ﬁrst to provide a quantitative analysis with
clinical correlation that Her-2/neu induces angiogenesis and lym-
phangiogenesis and plays a role in the biological and behavioral(TSP-1) expression in the tumor area (TSP-1/T) accompanied by high TSP-1 expression
cation. Pattern 2 is high TSP-1/T accompanied by low TSP-1/S, shown at (C) 100
5 mm (B, D).
Table 3
The correlation of angiogenesis (MVD) and lymphangiogenesis (LVD) with TSP-1
expression in the tumor or stromal area.
TSP-1/T p TSP-1/S p
<2 2 <2 2
No. 23 33 27 29
MVD 12.4  4.5 9.8  3.7 0.018 9.4  3.6 12.2  4.4 0.015
LVD 4.0  1.9 3.6  1.5 0.333 3.5  1.5 3.9  1.9 0.372
Data are expressed as mean  standard deviation.
LVD ¼ lymphatic vessel density; MVD ¼ microvessel density; TSP-1/
S ¼ thrombospondin-1 expression in the stromal area; TSP-1/T ¼ thrombospondin-
1 expression in the tumor area.
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ampliﬁcation has a greater prognostic value than most currently
used prognostic factors, including hormonal receptor status, in
early breast cancer or lymph node-positive disease.29 Its signiﬁ-
cance remained even after adjusting for other known prognostic
factors.1 In our data, Her-2/neu expression was correlated with less
ER and PR expression and more Ki-67 expression. It also supports
the concept that ER-negative tumors are a morphologically and
phenotypically distinct entity and provides a rationale for the study
and for use of newer agents in breast cancer treatment.30
Her-2/neu stimulates tumor growth, at least in part, by upre-
gulating angiogenesis.4 Some angiogenic activators and/or in-
hibitors have been proposed as the mediators that were reported
by Izumi et al5 in herceptin-induced normalization and regression
of the vasculature in an experimental Her-2/neu overexpressing
breast tumor model. The knockdown of Her-2/neu expression by
small interfering RNA (siRNA) further elucidates the speciﬁc asso-
ciation of increased expression of the antiangiogenic factor TSP-1
with decreased expression of the proiangiogenic VEGF.4 Our data
indicated that Her-2/neu-induced angiogenesis is related to TSP-1
expression. In addition, Her-2/neu-related angiogenesis is also
explained by the constitutive activation of oncogenic proteins (e.g.,
EGRF, Raf, MEK, and PI3K) acting at various levels in the RasFig. 4. The correlation between MVD, LVD and the different Her-2/neu, TSP-1/T, and TSP-1
(r ¼ 0.662, p < 0.001) and LVD (r ¼ 0.574, p < 0.001). MVD is negatively correlated with TSP-
LVD is correlated with neither TSP-1/T (r ¼ e0.201, p ¼ 0.138) nor TSP-1/S (r ¼ 0.180
S ¼ thrombospondin-1 expression in adjacent stroma; TSP-1/T ¼ thrombospondin-1 expresignaling pathway, which simultaneously induces TSP-1 down-
regulation and VEGF upregulation.31
Lymphangiogenesis (in addition to angiogenesis) is a commonly
reported histopathological ﬁnding and is essential for breast cancer
progression and patient survival.32 Her-2/neu-related lymphangio-
genesis in breast cancer has attracted attention in recent years.33,34
In the absence of effective immunohistochemical markers of
lymphatic endothelium in parafﬁn sections, lymphatic invasion can
only be identiﬁed on the basis of conventional hematoxylin and
eosin (H&E) staining because the presence of tumor emboli within
vascular channels is distinctly lined by a single layer of endothelial
cells. Therefore, some contradictory results have been reported
when applying immunohistochemistry because of a lack of stan-
dards for antibodies, preparation, ﬁxation, staining procedure, and
analysis for different choices of cut-off points.35 With the avail-
ability of a selectivemarker for the lymphatic endothelium (e.g., the
D2-40 monoclonal antibody), the increased accuracy of detecting
lymphatic invasion can contribute to the evaluation of the utility of a
qualitative and quantitative assessment as a prognostic indicator in
invasive cancer.20 In our study, overexpression of Her-2/neu in
breast cancer is associatedwith a high LVD. The speciﬁcity of D2-40-
stained lymphatic vessels was evidenced by some arterioles
showing characteristic lumen-like structures but no staining for D2-
40 (Fig. 2B). Bhattacharjee et al33 recently indicated that Her-2/neu
interacts with cyclooxygenase-2 in the upregulation of VEGF-C and
in lymphangiogenesis.
Our data showed that Her-2/neu-induced lymphangiogenesis is
unrelated to TSP-1 expression. The role of TSP-1 in lymphagio-
genesis was unclear prior to the availability of speciﬁc lymphatic
markers that distinguish lymphatic from vascular endothelium.
Our ﬁnding is concordant with the report by Hawighorst et al36
that showed that TSP-1 overexpression suppresses tumor angio-
genesis and distant organ metastasis, but it failed to inhibit tumor-
associated lymphangiogenesis or lymphatic tumors from spreading
to regional lymph nodes in a transgenic mouse skin cancer model.
Concomitant with these results, the endothelial TSP-1 receptor
CD36 is mostly absent from cutaneous lymphatic vessels.36 The/S expression groups. The expression of Her-2/neu is positively correlated with MVD
1/T (r ¼ e0.414, p ¼ 0.002) and positively correlated with TSP-1/S (r ¼ 0.471, p < 0.001).
, p ¼ 0/185). LVD ¼ lymphatic vessel density; MVD ¼ microvessel density; TSP-1/
ssion in tumor cells.
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(e.g., the upregulation of VEGF-C and VEGF-D in a Her-2/neu-
dependent pattern) that facilitate lymphangiogenesis and the
spreading of tumors cells to the lymph nodes in breast carcinoma
and in lung carcinoma.19,37,38
Stromal reaction is a host reaction of connective tissue that,
when induced in cancer, produces a progressive and permissive
mesenchymal microenvironment, thereby supporting tumor pro-
gression.39 The locally activated host microenvironment, which
includes cellular and extracellular elements, then modiﬁes the
proliferative and invasive behavior of the tumor cells.40 Our pre-
vious study demonstrated a novel role of TSP-1 in inhibiting the
tumor-stroma reaction that could be attributed to the blockage of
activated ﬁbroblasts from invading cancer cells, in addition to its
antiangiogenesis effect. The increased migration ability and the
invasive ability into the tumor cluster of activated ﬁbroblasts are
inhibited by TSP-1.41 The TSP-1 expression in tumors and in the
stromamodulates the pericellular environment and can potentially
change the tumor-extracellular matrix (ECM) microenvironment to
avoid further progression. The remodeling connective tissue in-
teracts with epithelial cells and controls tumor invasion and
angiogenesis.42 Changes in the tumor-ECM microenvironment
further support the concept of stromal reaction happening in par-
allel to tumorigenesis.41
In this study, two unique expression patterns of TSP-1 were
found, and they were correlated with different Her-2/neu expres-
sion and angiogenesis. Low TSP-1 expression in tumor cells coex-
isting with high TSP-1 expression in surrounding stromal areas (i.e.,
desmoplasia) induced higher angiogenesis. The spatial correlation
of high Her-2/neu expression and low TSP-1 expression in the tu-
mor area implies that Her-2/neumay downregulate TSP-1 in tumor
areas, and have a subsequent compensatory response from the
surrounding stroma and a ﬁnal angiogenic balance falling on the
side of the tumor area instead of the stroma area. In a study by
Bertin et al17 the presence of TSP-1 in desmoplasia alonedbut not
the total TSP-1 mRNA expressiondwas correlated with the angio-
genic status. This is conceivable because TSP-1 mRNA was
expressed in the tumor and in the surrounding stroma. By using the
ACIS, we could further speciﬁcally localize and quantitate both
areas separately. Another explanation is that there are more factors
(e.g., VEGFs) involved in the angiogenesis balance in addition to
TSP-1. A single factor cannot explain the whole proangiogenic or
antiangiogenic microenvironment.26 From our observation, a hy-
pothetical model could be proposed in which Her-2/neu augments
tumor angiogenesis, at least in part, by lowering TSP-1 expression
in tumor areas, thereby resulting in high stromal reaction
as compensation. Because the resultant angiogenesis status coin-
cided with TSP-1 expression in the tumor area, TSP-1 in stroma
areas plays a compensatory role in the change of TSP-1 expression
in the stroma area. The hypothetical model is supported by
the compensatory response mode of matrix metallopreotease
providing an alternative paracrine support for tumor angiogen-
esis.43 Thus, TSP-1/T may play an active role and TSP-1/S may play a
passive and compensatory role for microenvironmental changes in
breast cancer.
The limitations of this study are as follows: (1) only a correlative
phenomenon was demonstrated; therefore a causeeeffect rela-
tionship was not available and (2) some selection bias of LVD may
exist because of an insufﬁcient number of lymphatic vessels visible
in the high-power-ﬁelds on acccount of the inherent paucity of
lymphatic vessels. The biological signiﬁcance of the presence of
D2–40 in the normal myoepithelia cells remains unknown. Dumoff
et al27 reported positive D2-40 immunoreactivity in cervical cancer
tissues that was correlated with lymphatic invasion and nodal
metastasis in early stage cervical squamous cell carcinoma.In conclusion, our data support the observation that Her-2/neu
can affect biological manifestations of breast cancer by increasing
angiogenesis which is TSP-1-related and increasing lymphangio-
genesis which is TSP-1-unrelated. Two distinct expression patterns
of TSP-1 occur in accordance with the Her-2/neu expression levels,
thereby resulting in different angiogenic status. Our ﬁndings
further provide correlative evidence for the hypothetical concept
that Her-2/neu augments tumor angiogenesis, at least in part, by
lowering TSP-1 expression in tumor areas, thereby resulting in a
high stromal reaction as compensation. From our results and ob-
servations, combined herceptin and antiangiogenesis treatment
may have synergistic antitumor effects in Her-2/neu overexpression
in breast cancer patients.Acknowledgments
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